top of page
Case Studies - Pricing
Case Study: LSO
AMNOG Impact on Launch Sequence
A global pharmaceutical company was facing the following issue:
Goal: EU plus Turkey peak sales forecast of $1.1BN with 10-year total cumulative forecast of $8.3BN.
Strategy: Post EMA approval launch first in Germany.
Risk: AMNOG price cut may impact global revenues.
EAI Solution: Recommendation to delay launch in Germany by 8 months
If the IQWiG benefit appraisal concludes less benefit or no additional benefit, like for 37% of cases, the company will risk losing $305M in 10-year global revenue based on a 44% price cut post price negotiation with GKV.
If the benefit appraisal is considerable to minor, like for 63% of cases, the company will risk losing $71M in 10-year global revenue based on a price cut of 23%.
Early payer assessment, comparator analogues and competitor launch impact led to a high probability of a rebate in excess of 23%.
RESULTS: Client changed their launch plan in order to maximize global revenues
1.Significant improvement in pricing agility through global pricing intelligence.
2.Key insights and identification of high risk markets.
3.Execution of pricing strategies designed to optimize launch plan.
bottom of page